Protect and profit: the (prior) art of patents

Published: 28-Mar-2017
Patient Experience

Patents protect technical concepts and enable the proprietor to control the exploitation of the protected invention. Nowhere is this more significant than in the life sciences sector, which must continually invest in developing groundbreaking new products to support medical progression

You need to be a subscriber to read this article.
Click here to find out more.

It faces the added difficulty of attempting to strike the appropriate balance between the sizeable investment required and achieving a sustainable monopoly regarding the benefits.

Elliott Davies, European Patent Attorney at Wynne Jones IP, advises on how inventors can protect their inventions and adapt them to ensure market exclusivity.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Wynne Jones IP
See more

You may also like

Research & Development

Why intellectual property is vital to the success of R&D

Read more
Life changing medicinal breakthroughs and cutting-edge surgical technology just would not exist without vital research and development

Trending Articles

  1. Ilya Pharma awarded engineered lactic acid bacterial strain patent The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
  2. Locate Bio is granted key US and EU patents for its IntraStem non-viral, next generation gene delivery technology Locate Bio, a cell and gene therapy platform company developing a pipeline of regenerative medicine products, has received notification that it will be granted key patents covering its IntraStem technology in the United States and Europe
  3. Approaching the abyss For years, pharma pundits have been issuing increasingly dire warnings about the lack of new drugs
  4. US more favourable to drug innovation than Europe Pharma industry also reveals concern about regulatory and IP system in Europe
  5. Why intellectual property is vital to the success of R&D Life changing medicinal breakthroughs and cutting-edge surgical technology just would not exist without vital research and development

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Why intellectual property is vital to the success of R&D

Life changing medicinal breakthroughs and cutting-edge surgical technology just would not exist without vital research and development
Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Subscribe now